Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck KGaA/Pfizer's 90 day exclusivity period in effect now

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 23, 2022 11:22am

177 Views

Post# 35122022

RE:RE:RE:RE:RE:Merck KGaA/Pfizer's 90 day exclusivity period in effect now

Bracelet-1 became fully enrolled in June 2022 - add 160 days for data assessment and that takes the timeline to the end of October 2022. Once the 160 days elapsed in October, the 90 day exclusivity period came into effect.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario